Keywords
Primary
Immune thrombocytopenia
Submitted : 2023-06-20
Accepted : 2023-07-05
Published : 2023-07-20
Abstract
Objective: To explore the effect of low-dose rituximab in primary immune thrombocytopenia. Methods: From January 2022 to January 2023, 60 patients with primary immune thrombocytopenia were randomly divided into two groups. The control group was treated with standard doses of rituximab, and the observation group was treated with low doses of rituximab. Rituximab was used for treatment, and the clinical curative effect of the two groups was observed. Results: Before treatment, there was no statistically significant difference in platelet count (PLT), anti-GPⅡb/Ⅲa antibody, and anti-GPⅠb/Ⅸ antibody between the two groups (P > 0.05). After treatment, the PLT of the two groups increased significantly. Antibodies were all decreased, and there was no significant difference between the two groups (P > 0.05). The incidence of adverse reactions in the observation group was 13.33%, and that in the control group was 40.00%. The adverse reactions in the observation group were significantly lower than the control group (P < 0.05). Conclusion: In the clinical treatment of primary immune thrombocytopenia, low-dose rituximab can control the progression of the disease, improve blood routine indicators, and have fewer adverse reactions.
References
Liu C, Luan L, 2019, The Effect of Glucocorticoid Combined with Low-Dose Rituximab Injection in the Treatment of Refractory Primary Immune Thrombocytopenia. China Contemporary Medicine, 26(30): 68–70 + 74.
Yan L, Zhang J, Ding X, 2021, Effect Analysis of Low-Dose Rituximab Combined with Prednisone Acetate Tablets in the Treatment of Primary Immune Thrombocytopenia. Clinical Medicine Engineering, 28(11): 1505–1506.
Zhang Y, Du J, 2021, Clinical Curative Effect Analysis of Low-Dose and Standard-Dose Rituximab on Elderly Patients with Chronic Refractory Primary Immune Thrombocytopenia. Shanxi Medical Journal, 50(1): 56–58.
Hu X, Luo Y. Comparison of the Effect of Standard-Dose and Low-Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia. Chinese and Foreign Medical Research, 19(2): 30–32.
Hu X, Bao G, Wang H, et al, 2020, Efficacy of Low-Dose Rituximab and Cyclosporine in the Treatment of Refractory Primary Immune Thrombocytopenia and Safety Analysis. Chinese Medicine and Clinic, 20(20): 3476–3478.
Li J, Chen L, Jiang G, et al, 2021, Efficacy and Safety Analysis of Low-Dose Rituximab in the Treatment of Refractory Thrombocytopenia Secondary to Systemic Lupus Erythematosus. Jilin Medicine, 42(4): 966–969.
Zhu X, Ma J, Gu H, et al, 2021, Analysis of Clinical Characteristics of Primary Chronic Refractory Immune Thrombocytopenia in Children in a Single Center. Journal of Clinical Hematology, 34(11): 781–784.
Zhang Y, Du J, 2021, Clinical Curative Effect Analysis of Low-Dose and Standard-Dose Rituximab on Elderly Patients with Chronic Refractory Primary Immune Thrombocytopenia. Shanxi Medical Journal, 50(1): 56–58.
Yan L, Zhang J, Ding X, 2021, Effect Analysis of Low-Dose Rituximab Combined with Prednisone Acetate Tablets in the Treatment of Primary Immune Thrombocytopenia. Clinical Medicine Engineering, 28(11): 1505–1506.
Zhu X, Ma J, Chen Z, et al, 2022, Comparison of the Efficacy and Safety of Two Small Doses of Rituximab in the Second-Line Treatment of Children with Primary Immune Thrombocytopenia. Chinese Journal of Pediatrics, 60(11): 1185–1190.